Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Cross-reactivity00:42

Cross-reactivity

Overview
Special Features of Adaptive Immunity01:20

Special Features of Adaptive Immunity

The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
Humoral Immune Responses01:36

Humoral Immune Responses

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reassessing Carotenoid Photophysics: Shedding Light on Dark States.

Journal of the American Chemical Society·2026
Same author

Generation Using Phage-Display of pH-Dependent Antibodies Against the Tumor-Associated Antigen AXL.

Antibodies (Basel, Switzerland)·2025
Same author

Feasibility of Anti-CEA Dye Conjugate for Cancer-Specific Imaging in Gastric Cancer Cell Lines and Mouse Xenograft Models.

Cancers·2025
Same author

The Arming of Natural Killer Cells With Fc-Engineered Monoclonal Antibodies Confers Specificity Against Tumor B Cells.

MedComm·2025
Same author

Singlet fission in heterogeneous lycopene aggregates.

Scientific reports·2025
Same author

Correction: Perylene-derivative singlet exciton fission in water solution.

Chemical science·2024

Related Experiment Video

Updated: Jun 17, 2026

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

[Bispecific antibodies: what future?].

André Pèlegrin1, Bruno Robert

  • 1Institut de recherche en cancérologie de Montpellier (IRCM), Montpellier, F-34298, France ; Inserm U896, Montpellier, F-34298, France. andre.pelegrin@inserm.fr

Medecine Sciences : M/S
|December 29, 2009
PubMed
Summary
This summary is machine-generated.

Bispecific antibodies, engineered for enhanced therapeutic potential, offer improved cancer immunotherapy and radioimmunotherapy by targeting multiple epitopes or cells. These novel antibody derivatives show promise despite technical challenges.

More Related Videos

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Related Experiment Videos

Last Updated: Jun 17, 2026

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Area of Science:

  • Immunology
  • Biotechnology
  • Oncology

Context:

  • Monoclonal antibodies are successful therapeutics but are monospecific.
  • Native antibodies bind to Fc receptors, influencing effector functions.
  • Cancer therapies seek to improve antibody-mediated cytotoxicity.

Purpose:

  • To explore the design and applications of bispecific antibodies.
  • To enhance antibody-based cancer immunotherapies and radioimmunotherapies.
  • To investigate novel strategies for antibody engineering.

Summary:

  • Bispecific antibodies are engineered to recognize multiple targets, overcoming the limitations of monospecific antibodies.
  • Strategies include quadroma, thioether-linked Fab' fragments, and genetic engineering.
  • Applications involve bridging tumor and T cells for immunotherapy or combining with radiolabeled haptens for radioimmunotherapy.
  • Further uses include targeting multiple antigens on a single cell or different epitopes on the same antigen.

Impact:

  • Bispecific antibodies represent a promising advancement in antibody-derived therapeutics.
  • They offer enhanced capabilities for cancer treatment and other applications.
  • Continued development is expected despite current technical constraints.